PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.

Patel, Rajvi; Fein, Daniel; Ramirez, Carolina B; Do, Kevin; Saif, Muhammad W

Patel, Rajvi; Fein, Daniel; Ramirez, Carolina B; Do, Kevin; Saif, Muhammad W.

Afiliação

Patel R; Northwell Health Cancer Institute and Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, NY, USA.
Fein D; Tufts University, School of Medicine, Tufts Cancer Center, Boston, MA, USA.
Ramirez CB; Northwell Health Cancer Institute and Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, NY, USA.
Do K; Tufts University, School of Medicine, Tufts Cancer Center, Boston, MA, USA.
Saif MW; Northwell Health Cancer Institute and Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, NY, USA.

Pancreas (Fairfax) ; 3(1): e5-e8, 2019.

Article em En | MEDLINE | ID: mdl-32030362

Palavras-chave

BRCA1/2; Chemoresistance; DNA damage repair; Genomics; Germline mutations; Pancreatic cancer; Synthetic lethality

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Pancreas (Fairfax) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google